Bannayan-Riley-Ruvalcaba syndrome natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "__NOTOC__ {{Bannayan-Riley-Ruvalcaba syndrome}} {{CMG}}; {{AE}} {{VKG}} ==Overview== If left untreated, [#]% of patients with [disease name] may progress to develop [manifes...")
 
 
Line 5: Line 5:


==Overview==
==Overview==
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
The symptoms of BRRS usually develop in the first decade of life.The [[prognosis]] is unknown for [[Bannayan-Riley-Ruvalcaba syndrome]] (BRRS).


OR
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
OR
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
==Natural History, Complications, and Prognosis==
==Natural History, Complications, and Prognosis==
 
'''Natural History'''
===Natural History===
*The symptoms of BRRS usually develop in the first decade of life, and start with symptoms such as [[developmental delay]], [[macrocephaly]] and [[Penis|penile]] lentigines.
*The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
'''Complications'''
*The symptoms of (disease name) typically develop ___ years after exposure to ___.
*Common [[complications]] of [[Bannayan-Riley-Ruvalcaba syndrome]] (BRRS) include:<ref name="pmid20301661">{{cite journal |vauthors=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, Eng C |title= |journal= |volume= |issue= |pages= |date= |pmid=20301661 |doi= |url=}}</ref><ref name="pmid211904482">{{cite journal |vauthors=Laury AR, Bongiovanni M, Tille JC, Kozakewich H, Nosé V |title=Thyroid pathology in PTEN-hamartoma tumor syndrome: characteristic findings of a distinct entity |journal=Thyroid |volume=21 |issue=2 |pages=135–44 |date=February 2011 |pmid=21190448 |doi=10.1089/thy.2010.0226 |url=}}</ref><ref name="pmid20962022">{{cite journal |vauthors=Smith JR, Marqusee E, Webb S, Nose V, Fishman SJ, Shamberger RC, Frates MC, Huang SA |title=Thyroid nodules and cancer in children with PTEN hamartoma tumor syndrome |journal=J. Clin. Endocrinol. Metab. |volume=96 |issue=1 |pages=34–7 |date=January 2011 |pmid=20962022 |doi=10.1210/jcem.96.3.zeg34a |url=}}</ref><ref name="pmid15067177">{{cite journal |vauthors=Zambrano E, Holm I, Glickman J, Huang S, Perez-Atayde A, Kozakewich HP, Shamberger RC, Nosé V |title=Abnormal distribution and hyperplasia of thyroid C-cells in PTEN-associated tumor syndromes |journal=Endocr. Pathol. |volume=15 |issue=1 |pages=55–64 |date=2004 |pmid=15067177 |doi= |url=}}</ref><ref name="pmid26700035">{{cite journal |vauthors=Ngeow J, Sesock K, Eng C |title=Breast cancer risk and clinical implications for germline PTEN mutation carriers |journal=Breast Cancer Res. Treat. |volume=165 |issue=1 |pages=1–8 |date=August 2017 |pmid=26700035 |doi=10.1007/s10549-015-3665-z |url=}}</ref><ref name="pmid26185318">{{cite journal |vauthors=Cameselle-Teijeiro J, Fachal C, Cabezas-Agrícola JM, Alfonsín-Barreiro N, Abdulkader I, Vega-Gliemmo A, Hermo JA |title=Thyroid Pathology Findings in Cowden Syndrome: A Clue for the Diagnosis of the PTEN Hamartoma Tumor Syndrome |journal=Am. J. Clin. Pathol. |volume=144 |issue=2 |pages=322–8 |date=August 2015 |pmid=26185318 |doi=10.1309/AJCP84INGJUVTBME |url=}}</ref><ref name="pmid145741565">{{cite journal |vauthors=Hendriks YM, Verhallen JT, van der Smagt JJ, Kant SG, Hilhorst Y, Hoefsloot L, Hansson KB, van der Straaten PJ, Boutkan H, Breuning MH, Vasen HF, Bröcker-Vriends AH |title=Bannayan-Riley-Ruvalcaba syndrome: further delineation of the phenotype and management of PTEN mutation-positive cases |journal=Fam. Cancer |volume=2 |issue=2 |pages=79–85 |date=2003 |pmid=14574156 |doi= |url=}}</ref>
*If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
**Increased risk of following [[cancers]]:
 
***[[Thyroid cancer]]: Mostly commonly [[Follicular carcinoma of the Thyroid|follicular]], very rarely [[Papillary thyroid cancer|papillary]], but never [[medullary thyroid cancer]]
===Complications===
***[[Breast cancer]]
*Common complications of [disease name] include:
***[[Renal cell cancer]]
**[Complication 1]
***[[Granulosa cell tumour|Granulosa cell tumor]] of the [[ovary]]
**[Complication 2]
'''Prognosis'''
**[Complication 3]
*The [[prognosis]] is unknown for [[Bannayan-Riley-Ruvalcaba syndrome]] (BRRS).
 
===Prognosis===
*Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [--]%.
*Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
*The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
*[Subtype of disease/malignancy] is associated with the most favorable prognosis.
*The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.
 
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Latest revision as of 19:11, 22 March 2019

Template:Bannayan-Riley-Ruvalcaba syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

The symptoms of BRRS usually develop in the first decade of life.The prognosis is unknown for Bannayan-Riley-Ruvalcaba syndrome (BRRS).

Natural History, Complications, and Prognosis

Natural History

Complications

Prognosis

References

  1. ↑ Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean L, Stephens K, Amemiya A, Eng C. PMID 20301661. Vancouver style error: initials (help); Missing or empty |title= (help)
  2. ↑ Laury AR, Bongiovanni M, Tille JC, Kozakewich H, Nosé V (February 2011). "Thyroid pathology in PTEN-hamartoma tumor syndrome: characteristic findings of a distinct entity". Thyroid. 21 (2): 135–44. doi:10.1089/thy.2010.0226. PMID 21190448.
  3. ↑ Smith JR, Marqusee E, Webb S, Nose V, Fishman SJ, Shamberger RC, Frates MC, Huang SA (January 2011). "Thyroid nodules and cancer in children with PTEN hamartoma tumor syndrome". J. Clin. Endocrinol. Metab. 96 (1): 34–7. doi:10.1210/jcem.96.3.zeg34a. PMID 20962022.
  4. ↑ Zambrano E, Holm I, Glickman J, Huang S, Perez-Atayde A, Kozakewich HP, Shamberger RC, Nosé V (2004). "Abnormal distribution and hyperplasia of thyroid C-cells in PTEN-associated tumor syndromes". Endocr. Pathol. 15 (1): 55–64. PMID 15067177.
  5. ↑ Ngeow J, Sesock K, Eng C (August 2017). "Breast cancer risk and clinical implications for germline PTEN mutation carriers". Breast Cancer Res. Treat. 165 (1): 1–8. doi:10.1007/s10549-015-3665-z. PMID 26700035.
  6. ↑ Cameselle-Teijeiro J, Fachal C, Cabezas-Agrícola JM, Alfonsín-Barreiro N, Abdulkader I, Vega-Gliemmo A, Hermo JA (August 2015). "Thyroid Pathology Findings in Cowden Syndrome: A Clue for the Diagnosis of the PTEN Hamartoma Tumor Syndrome". Am. J. Clin. Pathol. 144 (2): 322–8. doi:10.1309/AJCP84INGJUVTBME. PMID 26185318.
  7. ↑ Hendriks YM, Verhallen JT, van der Smagt JJ, Kant SG, Hilhorst Y, Hoefsloot L, Hansson KB, van der Straaten PJ, Boutkan H, Breuning MH, Vasen HF, Bröcker-Vriends AH (2003). "Bannayan-Riley-Ruvalcaba syndrome: further delineation of the phenotype and management of PTEN mutation-positive cases". Fam. Cancer. 2 (2): 79–85. PMID 14574156.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Bannayan-Riley-Ruvalcaba_syndrome_natural_history,_complications_and_prognosis&oldid=1558819"